Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 2, 2014, Pages 126-137

  Capra, V ^a   Back M ^b   Angiolillo, D J ^c   Cattaneo, M ^a   Sakariassen, K S ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d KellSa sas   (Italy)

Author keywords

Cardiovascular diseases; Inflammation; Isoprostanes; Platelets; Thromboxane receptors

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTROBAN; ENDOPEROXIDE; IFETROBAN; ISOPROSTANE DERIVATIVE; LINOTROBAN; OZAGREL; PICOTAMIDE; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTANOID RECEPTOR; RAMATROBAN; RIDOGREL; SERATRODAST; SULOTROBAN; TERBOGREL; TERUTROBAN; THROMBOXANE A2; THROMBOXANE PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; AUTOCRINE EFFECT; BIOSYNTHESIS; BLEEDING; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HEMOSTASIS; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; OBESITY; OXIDATIVE STRESS; PARACRINE SIGNALING; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASCULITIS; VASOCONSTRICTION; VASODILATATION;

CARDIOVASCULAR DISEASES; INFLAMMATION; ISOPROSTANES; PLATELETS; THROMBOXANE RECEPTORS;

BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, THROMBOXANE; THROMBOSIS;

EID: 84893604297     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12472     Document Type: Review

References (104)

1. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998; 1425: 543-59.
2. Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001; 134: 1385-92.
3. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
4. Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS. HN-11500-a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 1994; 71: 103-9.
5. Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998; 40: 223-9.
6. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
7. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
8. Szuldrzynski K, Zalewski J, Machnik A, Zmudka K. Elevated levels of 8-iso-prostaglandin F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn 2010; 120: 19-24.
9. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
10. Wilson SJ, Cavanagh CC, Lesher AM, Frey AJ, Russell SE, Smyth EM. Activation-dependent stabilization of the human thromboxane receptor: role of reactive oxygen species. J Lipid Res 2009; 50: 1047-56.
11. Zucker TP, Bonisch D, Muck S, Weber AA, Bretschneider E, Glusa E, Schror K. Thrombin-induced mitogenesis in coronary artery smooth muscle cells is potentiated by thromboxane A2 and involves upregulation of thromboxane receptor mRNA. Circulation 1998; 97: 589-95.
12. Praticò D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 2008; 201: 8-16.
13. Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009; 27(Suppl. 3): 20-7.
14. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 2009; 5: 479-93.
15. Dogné JM, Hanson J, de Leval X, Praticò D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006; 12: 903-23.
16. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226.
17. Ting HJ, Murad JP, Espinosa EV, Khasawneh FT. Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting. J Cardiovasc Pharmacol Ther 2012; 17: 248-59.
18. Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 2645-51.
19. Kent KC, Collins LJ, Schwerin FT, Raychowdhury MK, Ware JA. Identification of functional PGH2/TxA2 receptors on human endothelial cells. Circ Res 1993; 72: 958-65.
20. Wikstrom K, Kavanagh DJ, Reid HM, Kinsella BT. Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide. Cell Signal 2008; 20: 1497-512.
21. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118: 18-35.
22. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 504-8.
23. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 183-6.
24. Moers A, Wettschureck N, Gruner S, Nieswandt B, Offermanns S. Unresponsiveness of platelets lacking both Galpha(q) and Galpha(13). Implications for collagen-induced platelet activation. J Biol Chem 2004; 279: 45354-9.
25. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998; 102: 1994-2001.
26. Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-52.
27. Samama M, Lecrubier C, Conard J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Lagarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Haematol 1981; 48: 293-303.
28. Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2. J Clin Invest 1981; 67: 1801-4.
29. Fuse I, Mito M, Hattori A, Higuchi W, Shibata A, Ushikubi F, Okuma M, Yahata K. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A2 activation. Blood 1993; 81: 994-1000.
30. Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987; 57: 158-64.
31. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-7.
32. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949-56.
33. Okuma M, Hirata T, Ushikubi F, Kakizuka A, Narumiya S. Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2. Pol J Pharmacol 1996; 48: 77-82.
34. Mumford AD, Dawood BB, Daly ME, Murden SL, Williams MD, Protty MB, Spalton JC, Wheatley M, Mundell SJ, Watson SP. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 2010; 115: 363-9.
35. Kamae T, Kiyomizu K, Nakazawa T, Tadokoro S, Kashiwagi H, Honda S, Kanakura Y, Tomiyama Y. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thromb Haemost 2011; 9: 1040-8.
36. Mumford AD, Nisar S, Darnige L, Jones ML, Bachelot-Loza C, Gandrille S, Zinzindohoue F, Fischer AM, Mundell SJ, Gaussem P. Platelet dysfunction associated with the novel Trp29Cys thromboxane A(2) receptor variant. J Thromb Haemost 2013; 11: 547-54.
37. Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP. EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Thromb Res 2012; 130: 746-52.
38. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
39. Davì G, Santilli F, Vazzana N. Thromboxane receptors antagonists and/or synthase inhibitors. Handb Exp Pharmacol 2012; 210: 261-86.
40. Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986; 77: 496-502.
41. Grad E, Pachino RM, FitzGerald GA, Danenberg HD. Role of thromboxane receptor in C-reactive protein-induced thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 2468-74.
42. Rollini F, Franchi F, Muniz-Lozano A, Angiolillo DJ. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 2013a; 6: 329-45.
43. Santilli F, Mucci L, Davì G. TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern Emerg Med 2011; 6: 203-12.
44. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B, Boneu B, Fiessinger JN. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3: 1437-45.
45. Fiessinger JN, Bounameaux H, Cairols MA, Clement DL, Coccheri S, Fletcher JP, Hoffmann U, Turpie AG. Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. J Thromb Haemost 2010; 8: 2369-76.
46. Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009; 28: 505-13.
47. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, Fratacci MD. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-22.
48. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-95.
49. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-52.
50. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 2011; 9: 2109-11.
51. Tello-Montoliu A, Rollini F, Desai B, Pasqualino G, Patel R, Sorensen AS, Sakariassen KS, Angiolillo DJ. Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. J Thromb Thrombolysis 2012; 34: 297-9.
52. Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muniz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. J Thromb Thrombolysis 2013b. in press.
53. Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. Eur J Clin Pharmacol 2013; 69: 459-65.
54. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
55. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 2004; 24: 1614-20.
56. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001; 103: 399-409.
57. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson Roberts L 2nd, Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433: 113-26.
58. Capra V, Bäck M, Barbieri SS, Camera M, Tremoli E, Rovati GE. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 2013; 33: 364-438.
59. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-40.
60. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, Lechi C. The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 1998; 18: 1248-56.
61. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJ 2nd, Hoover RL, Badr KF. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992; 90: 136-41.
62. Fontana L, Giagulli C, Cominacini L, Pasini AF, Minuz P, Lechi A, Sala A, Laudanna C. Beta2 integrin-dependent neutrophil adhesion induced by minimally modified low-density lipoproteins is mainly mediated by F2-isoprostanes. Circulation 2002; 106: 2434-41.
63. Beauchamp MH, Martinez-Bermudez AK, Gobeil F Jr, Marrache AM, Hou X, Speranza G, Abran D, Quiniou C, Lachapelle P, Roberts J 2nd, Almazan G, Varma DR, Chemtob S. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol 2001; 90: 2279-88.
64. Hou X, Roberts LJ 2nd, Taber DF, Morrow JD, Kanai K, Gobeil F Jr, Beauchamp MH, Bernier SG, Lepage G, Varma DR, Chemtob S. 2, 3-Dinor-5, 6-dihydro-15-F(2t)-isoprostane: a bioactive prostanoid metabolite. Am J Physiol Regul Integr Comp Physiol 2001; 281: R391-400.
65. Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997a; 17: 3230-5.
66. Reilly MP, Praticò D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-8.
67. Mehrabi MR, Ekmekcioglu C, Tatzber F, Oguogho A, Ullrich R, Morgan A, Tamaddon F, Grimm M, Glogar HD, Sinzinger H. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43: 492-9.
68. Praticò D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, Maclouf J, Violi F, FitzGerald GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-34.
69. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997b; 96: 69-75.
70. Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-203.
71. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 1038-42.
72. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106: 2800-5.
73. Cracowski JL, Baguet JP, Ormezzano O, Bessard J, Stanke-Labesque F, Bessard G, Mallion JM. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003; 41: 286-8.
74. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23: 434-9.
75. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
76. Pilz H, Oguogho A, Chehne F, Lupattelli G, Palumbo B, Sinzinger H. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb Res 2000; 99: 209-21.
77. Roberts CK, Vaziri ND, Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation 2002; 106: 2530-2.
78. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, Capra V, D'Orazio N. The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. Expert Opin Investig Drugs 2007; 16: 25-32.
79. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, Park BJ. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10.
80. Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, Brioschi M, Guerrini U, Castiglioni L, Blanc-Guillemaud V, Lerond L, Tremoli E, Sironi L. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol Exp Ther 2010; 334: 199-205.
81. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-204.
82. Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, Michiels C, Pirotte B, Masereel B, Sakalihassan N, Defraigne JO, Dogné JM. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat 2011; 94: 124-32.
83. Petri MH, Tellier C, Michiels C, Ellertsen IH, Dogné JM, Bäck M. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2013; 441: 393-8.
84. Leitinger N, Huber J, Rizza C, Mechtcheriakova D, Bochkov V, Koshelnick Y, Berliner JA, Binder BR. The isoprostane 8-iso-PGF(2alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation. FASEB J 2001; 15: 1254-6.
85. Nagata T, Uehara Y, Numabe A, Ishimitsu T, Hirawa N, Ikeda T, Matsuoka H, Sugimoto T. Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992; 263: H1331-8.
86. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-18.
87. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280-6.
88. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
89. Gelosa P, Sevin G, Pignieri A, Budelli S, Castiglioni L, Blanc-Guillemaud V, Lerond L, Tremoli E, Sironi L. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 2011; 300: H762-8.
90. Gautier-Veyret E, Arnaud C, Bäck M, Pepin JL, Petri MH, Baguet JP, Tamisier R, Levy P, Stanke-Labesque F. Intermittent hypoxia activated cyclooxygenase pathway: role in atherosclerosis. Eur Respir J 2012; 42: 404-13.
91. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007; 7: 1359-74.
92. Sakata K, Dahlen SE, Bäck M. The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. Br J Pharmacol 2004; 141: 449-56.
93. Foudi N, Norel X, Rienzo M, Louedec L, Brink C, Michel JB, Bäck M. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol 2009; 297: H1882-8.
94. Pfister SL. Aortic thromboxane receptor deficiency alters vascular reactivity in cholesterol-fed rabbits. Atherosclerosis 2006; 189: 358-63.
95. Gabrielsen A, Qiu H, Bäck M, Hamberg M, Hemdahl AL, Agardh H, Folkersen L, Swedenborg J, Hedin U, Paulsson-Berne G, Haeggstrom JZ, Hansson GK. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J Mol Med (Berl) 2010; 88: 795-806.
96. Praticò D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-6.
97. Cyrus T, Ding T, Praticò D. Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition. Atherosclerosis 2010; 208: 376-81.
98. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-94.
99. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-42.
100. Cyrus T, Yao Y, Ding T, Dogné JM, Praticò D. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 2007; 109: 3291-6.
101. Zhuge X, Arai H, Xu Y, Murayama T, Kobayashi T, Narumiya S, Kita T, Yokode M. Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cells. Biochem Biophys Res Commun 2006; 351: 865-71.
102. Tang M, Cyrus T, Yao Y, Vocun L, Praticò D. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 2005; 112: 2867-74.
103. Sarkis A, Roman RJ. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab 2004; 5: 245-56.
104. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 2005; 38: 1032-6.